Technical Analysis for LNTH - Lantheus Holdings, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
MACD Bearish Signal Line Cross | Bearish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Gapped Up | Strength | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Inside Day | Range Contraction | -0.21% | |
Wide Bands | Range Expansion | -0.21% | |
Outside Day | Range Expansion | -0.84% | |
Wide Bands | Range Expansion | -0.84% | |
Inside Day | Range Contraction | -2.43% | |
Wide Bands | Range Expansion | -2.43% |
Alert | Time |
---|---|
Fell Below Previous Day's Low | about 18 hours ago |
Gap Up Closed | about 18 hours ago |
60 Minute Opening Range Breakdown | about 18 hours ago |
Reversed from Up | about 18 hours ago |
Up 2% | about 19 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 08/01/2024
Lantheus Holdings, Inc. Description
Lantheus Holdings, Inc. is engaged in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products that assist clinicians in the diagnosis of cardiovascular and other diseases. The Company's medical imaging agents are used to diagnose coronary artery disease, congestive heart failure, stroke, peripheral vascular disease and other diseases. The Company's products include contrast agents and medical radiopharmaceuticals, including technetium generators. The Company's products include DEFINITY, TechneLite, Xenon Xe 133 Gas, Cardiolite, Neurolite, Thallium Tl 201, Gallium Ga 67, Gludef, Quadramet and Ablavar. The Company is also engaged in developing agents, such as Flurpiridaz F 18, which is a myocardial perfusion imaging agent; 18F LMI 1195, which is a cardiac neuronal imaging agent, and LMI 1174, which is a vascular remodeling imaging agent.
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Disease Chemical Elements Prostate Cancer Heart Failure Medical Imaging Stroke Medical Physics Artery Perfusion Artery Disease Imaging Agent Peripheral Vascular Disease Radiopharmaceuticals Congestive Heart Failure Coronary Artery Disease Gallium Neuron Cardiovascular And Other Diseases Medicinal Radiochemistry Myocardial Perfusion Imaging
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 126.8899 |
52 Week Low | 50.2 |
Average Volume | 1,052,422 |
200-Day Moving Average | 70.24 |
50-Day Moving Average | 89.80 |
20-Day Moving Average | 103.61 |
10-Day Moving Average | 116.52 |
Average True Range | 4.99 |
RSI (14) | 64.16 |
ADX | 41.83 |
+DI | 32.21 |
-DI | 15.14 |
Chandelier Exit (Long, 3 ATRs) | 111.92 |
Chandelier Exit (Short, 3 ATRs) | 91.06 |
Upper Bollinger Bands | 140.45 |
Lower Bollinger Band | 66.77 |
Percent B (%b) | 0.62 |
BandWidth | 71.12 |
MACD Line | 8.72 |
MACD Signal Line | 9.06 |
MACD Histogram | -0.3416 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 117.71 | ||||
Resistance 3 (R3) | 118.14 | 116.89 | 116.88 | ||
Resistance 2 (R2) | 116.89 | 115.62 | 116.68 | 116.60 | |
Resistance 1 (R1) | 114.80 | 114.83 | 114.18 | 114.38 | 116.32 |
Pivot Point | 113.56 | 113.56 | 113.24 | 113.34 | 113.56 |
Support 1 (S1) | 111.46 | 112.28 | 110.84 | 111.04 | 109.10 |
Support 2 (S2) | 110.22 | 111.49 | 110.01 | 108.82 | |
Support 3 (S3) | 108.13 | 110.22 | 108.54 | ||
Support 4 (S4) | 107.71 |